Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform

Core Insights - The article discusses the advancements in in vivo gene editing of hematopoietic stem cells (HSCs) using Sana Biotechnology's fusogen technology, highlighting its potential to transform treatments for diseases like sickle cell disease and beta thalassemia [1][2][3] Group 1: Technology and Applications - Fusogen technology enables potent and specific in vivo delivery of gene-editing tools to HSCs, demonstrating effective editing in murine models [1][5] - The technology can deliver diverse payloads, including CRISPR and base-editing machinery, broadening its application beyond T cells to HSCs [1][3] - The platform aims to eliminate the need for conditioning chemotherapy, reducing side effects and simplifying the treatment process for patients [2][3] Group 2: Future Developments - Sana is developing SG293, a CD8-targeted fusosome for creating CD19-directed CAR T cells in vivo, with plans to file an IND for B-cell cancers and autoimmune diseases by 2027 [1][3] - The publication emphasizes the potential of fusogen technology to reach long-term multipotent HSCs in their natural bone marrow niche while avoiding off-target effects [2][3] Group 3: Company Overview - Sana Biotechnology, Inc. focuses on creating engineered cells as medicines, aiming to repair genes and replace damaged cells to improve patient outcomes [4]